Quality measures in heart failure US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Quality measures in heart failure. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Quality measures in heart failure US Medical PG Question 1: A 76-year-old woman seeks evaluation at a medical office for chest pain and shortness of breath on exertion of 3 months' duration. Physical examination shows bilateral pitting edema on the legs. On auscultation, diffuse crackles are heard over the lower lung fields. Cardiac examination shows jugular venous distention and an S3 gallop. Troponin is undetectable. A chest film shows cardiomegaly and pulmonary edema. Which of the following medications would be effective in lowering her risk of mortality?
- A. Propranolol
- B. Digoxin
- C. Lisinopril (Correct Answer)
- D. Furosemide
- E. Verapamil
Quality measures in heart failure Explanation: ***Lisinopril***
- The patient presents with classic signs and symptoms of **heart failure**, including dyspnea on exertion, bilateral pitting edema, jugular venous distention, S3 gallop, cardiomegaly, and pulmonary edema. **ACE inhibitors** like lisinopril are cornerstone therapy for **heart failure with reduced ejection fraction (HFrEF)** and significantly reduce mortality.
- They work by blocking the **renin-angiotensin-aldosterone system (RAAS)**, leading to **vasodilation**, reduced preload and afterload, and prevention of cardiac remodeling.
*Propranolol*
- While beta-blockers are used in heart failure, **non-selective beta-blockers** like propranolol are generally not preferred due to potential for exacerbating symptoms in acutely decompensated heart failure and lack of evidence for mortality benefit in this context.
- **Cardioselective beta-blockers** (e.g., carvedilol, metoprolol succinate) are used in stable heart failure, but propranolol's broad effects make it less suitable for this specific indication, especially when there are signs of decompensation.
*Digoxin*
- Digoxin can improve symptoms and reduce hospitalizations in heart failure, but it **does not demonstrate a mortality benefit** in patients with heart failure.
- It is primarily used for **symptom control** in patients with HFrEF, especially those with coexisting **atrial fibrillation**.
*Furosemide*
- Furosemide is a **loop diuretic** that is highly effective at reducing fluid overload and improving symptoms like pulmonary edema and peripheral edema in heart failure.
- However, while it improves symptoms and quality of life, furosemide **does not independently reduce mortality** in heart failure.
*Verapamil*
- Verapamil, a **non-dihydropyridine calcium channel blocker**, is generally **contraindicated** in heart failure with reduced ejection fraction (HFrEF) because it can worsen cardiac function and increase mortality.
- It has **negative inotropic effects**, which can further impair the already weakened pumping ability of the heart.
Quality measures in heart failure US Medical PG Question 2: A 64-year-old man presents to his physician for a scheduled follow-up visit. He has chronic left-sided heart failure with systolic dysfunction. His current regular medications include captopril and digoxin, which were started after his last episode of symptomatic heart failure approximately 3 months ago. His last episode of heart failure was accompanied by atrial fibrillation, which followed an alcohol binge over a weekend. Since then he stopped drinking. He reports that he has no current symptoms at rest and is able to perform regular physical exercise without limitation. On physical examination, mild bipedal edema is noted. The physician suggested to him that he should discontinue digoxin and continue captopril and scheduled him for the next follow-up visit. Which of the following statements best justifies the suggestion made by the physician?
- A. Long-term digoxin therapy produces significant survival benefits in patients with heart failure, but at the cost of increased heart failure-related admissions.
- B. Both captopril and digoxin are likely to improve the long-term survival of the patient with heart failure, but digoxin has more severe side effects.
- C. Captopril is likely to improve the long-term survival of the patient with heart failure, unlike digoxin.
- D. Digoxin does not benefit patients with left-sided heart failure in the absence of atrial fibrillation.
- E. Digoxin is useful to treat atrial fibrillation, but does not benefit patients with systolic dysfunction who are in sinus rhythm. (Correct Answer)
Quality measures in heart failure Explanation: ***Digoxin is useful to treat atrial fibrillation, but does not benefit patients with systolic dysfunction who are in sinus rhythm.***
- The patient's **atrial fibrillation** was likely triggered by the alcohol binge and has since resolved, suggesting he is now in **sinus rhythm**.
- Digoxin's primary benefit in heart failure with **systolic dysfunction** (HFrEF) is to control ventricular rate in patients with **atrial fibrillation**, but it does not offer survival benefit in HFrEF patients who are in **sinus rhythm** and well-managed with other therapies.
*Long-term digoxin therapy produces significant survival benefits in patients with heart failure, but at the cost of increased heart failure-related admissions.*
- This statement is incorrect; digoxin has been shown to **reduce hospital admissions** for heart failure, but it does **not provide a significant survival benefit** in patients with HFrEF in sinus rhythm.
- The main benefit of digoxin in HFrEF is to improve symptoms and quality of life, alongside reducing hospitalizations, but not prolonging life.
*Both captopril and digoxin are likely to improve the long-term survival of the patient with heart failure, but digoxin has more severe side effects.*
- **Captopril (an ACE inhibitor)** does improve **long-term survival** in heart failure, but **digoxin does not** demonstrably improve survival.
- While digoxin can have side effects, its lack of survival benefit for HFrEF in sinus rhythm is the primary reason for discontinuation, not just side effect severity.
*Captopril is likely to improve the long-term survival of the patient with heart failure, unlike digoxin.*
- This statement is partially correct that **captopril improves survival**, but it does not fully explain the physician's decision to discontinue digoxin.
- The key missing piece is the patient's current **sinus rhythm** and the lack of benefit of digoxin in that specific context for HFrEF.
*Digoxin does not benefit patients with left-sided heart failure in the absence of atrial fibrillation.*
- This statement is nearly correct, but "left-sided heart failure" is broad. It is specifically in patients with **systolic dysfunction (HFrEF)** who are in **sinus rhythm** that digoxin lacks significant benefit beyond symptom control, and does not provide survival benefit.
Quality measures in heart failure US Medical PG Question 3: The serum brain natriuretic peptide and N-terminal pro-BNP are elevated. A diagnosis of heart failure with preserved ejection fraction is made. In addition to supplemental oxygen therapy, which of the following is the most appropriate initial step in management?
- A. Intravenous dobutamine
- B. Intravenous furosemide therapy (Correct Answer)
- C. Intravenous morphine therapy
- D. Thoracentesis
- E. Intermittent hemodialysis
Quality measures in heart failure Explanation: ***Intravenous furosemide therapy***
- Heart failure with **preserved ejection fraction (HFpEF)** often presents with **pulmonary congestion** due to elevated filling pressures.
- **Furosemide**, a loop diuretic, effectively reduces fluid overload and associated symptoms by increasing renal excretion of sodium and water.
*Intravenous dobutamine*
- **Dobutamine** is an inotropic agent that increases myocardial contractility and heart rate.
- It is typically used for **acute decompensated heart failure with low cardiac output** and is generally avoided in HFpEF unless there is significant hypoperfusion, as it can worsen myocardial oxygen demand and diastolic dysfunction.
*Intravenous morphine therapy*
- **Morphine** can be used in acute heart failure to reduce preload and anxiety, but it is not a primary treatment for the underlying fluid overload.
- It can cause respiratory depression and hypotension, and its use is typically reserved for patients with severe pain or dyspnea not adequately managed by other therapies.
*Thoracentesis*
- **Thoracentesis** is indicated for symptomatic **pleural effusions** causing respiratory distress.
- While pleural effusions can occur in heart failure, initial management of generalized fluid overload typically involves diuretics, making thoracentesis a secondary intervention if diuretic therapy is insufficient.
*Intermittent hemodialysis*
- **Intermittent hemodialysis** is an invasive procedure primarily used for severe renal failure or refractory fluid overload that has not responded to maximal diuretic therapy.
- It is not the initial step in managing heart failure with preserved ejection fraction and would only be considered in highly selected cases with **acute kidney injury** or diuretic resistance.
Quality measures in heart failure US Medical PG Question 4: A 59-year-old African-American man presents with dyspnea on exertion and bilateral lower leg edema. The patient had a myocardial infarction 2 years ago, in which he developed chronic heart failure. Also, he has type 2 diabetes mellitus. His medications include bisoprolol 20 mg, lisinopril 40 mg, and metformin 2000 mg daily. The vital signs at presentation include: blood pressure is 135/70 mm Hg, heart rate is 81/min, respiratory rate is 13/min, and temperature is 36.6℃ (97.9℉). The physical examination is significant for bilateral lower leg pitting edema. The cardiac auscultation demonstrated an S3 and a systolic murmur best heard at the apex. Which of the following adjustments should be made to the patient’s treatment plan?
- A. Increase the dose of lisinopril
- B. Add hydralazine/isosorbide dinitrate (Correct Answer)
- C. Add amlodipine
- D. Add valsartan
- E. Increase the dose of bisoprolol
Quality measures in heart failure Explanation: ***Add hydralazine/isosorbide dinitrate***
- This patient is an **African-American** with **chronic HFrEF** who remains symptomatic despite ACE inhibitor and beta-blocker therapy.
- The **A-HeFT trial** demonstrated that **hydralazine/isosorbide dinitrate** reduces mortality and hospitalization in **African-American patients** with **NYHA class III-IV heart failure**.
- This combination is a **Class I recommendation** specifically for **self-identified African-American patients** with HFrEF who remain symptomatic on standard therapy (ACC/AHA guidelines).
- Among the options provided, this is the most appropriate addition, though in current practice, consideration would also be given to adding an **aldosterone antagonist** (spironolactone/eplerenone) or **SGLT2 inhibitor** if not yet prescribed.
*Increase the dose of lisinopril*
- The patient is already on **lisinopril 40 mg daily**, which is the **maximal recommended dose** for heart failure.
- Increasing the dose further would not provide additional benefit and could increase the risk of **hypotension**, **hyperkalemia**, or **renal dysfunction**.
*Add amlodipine*
- Amlodipine is a **dihydropyridine calcium channel blocker** that is generally **not recommended** for routine use in **HFrEF**.
- While it is **safe** in HFrEF (unlike non-dihydropyridines), it does **not improve mortality or morbidity** and does not address the underlying heart failure pathophysiology.
- It may be considered for refractory hypertension or angina in HFrEF patients, but this patient's BP is adequately controlled.
*Add valsartan*
- Valsartan is an **ARB** that would serve as an **alternative** to lisinopril (ACE inhibitor), not as an additional agent.
- **Combining ACE inhibitor + ARB** is generally **avoided** due to increased risk of **hyperkalemia**, **hypotension**, and **renal impairment** without significant mortality benefit.
- If an ARB were to be added, it would be in the form of **sacubitril/valsartan (ARNI)**, which would **replace** the ACE inhibitor, not supplement it.
*Increase the dose of bisoprolol*
- The patient is on **bisoprolol 20 mg**, but the typical **target dose for HFrEF is 10 mg daily**.
- The patient is already at or above the recommended target dose, and further increases would risk **bradycardia**, **hypotension**, and **fatigue** without clear additional benefit.
- Heart rate is already 81/min, suggesting adequate beta-blockade.
Quality measures in heart failure US Medical PG Question 5: A 70-year-old Caucasian male visits your office regularly for treatment of New York Heart association class IV congestive heart failure. Which of the following medications would you add to this man's drug regimen in order to improve his overall survival?
- A. Spironolactone (Correct Answer)
- B. Furosemide
- C. Amiloride
- D. Acetazolamide
- E. Hydrochlorothiazide
Quality measures in heart failure Explanation: ***Spironolactone***
- **Spironolactone** is an **aldosterone antagonist** that has been shown to reduce mortality and morbidity in patients with **NYHA Class III and IV heart failure**.
- It works by blocking the harmful effects of **aldosterone** on the heart, such as **fibrosis** and remodeling, improving cardiac function and survival.
*Furosemide*
- **Furosemide** is a **loop diuretic** primarily used to relieve **symptoms of congestion** (edema, dyspnea) in heart failure by promoting fluid excretion.
- While it improves symptoms, **furosemide** alone does not significantly improve long-term survival in patients with heart failure.
*Amiloride*
- **Amiloride** is a **potassium-sparing diuretic** that works by blocking sodium channels in the collecting duct, leading to modest diuresis.
- It is often used to prevent **hypokalemia** caused by other diuretics but does not have the same proven mortality benefit in heart failure as spironolactone.
*Acetazolamide*
- **Acetazolamide** is a **carbonic anhydrase inhibitor** primarily used for glaucoma, metabolic alkalosis, and altitude sickness.
- It has a weaker diuretic effect and is not a commonly used or recommended medication for improving long-term survival in patients with heart failure.
*Hydrochlorothiazide*
- **Hydrochlorothiazide** is a **thiazide diuretic** primarily used for hypertension and mild to moderate edema.
- While it can help manage fluid retention, it does not offer the same mortality benefit in advanced heart failure as aldosterone antagonists like spironolactone.
Quality measures in heart failure US Medical PG Question 6: A 72-year-old man presents to the outpatient clinic today. He has New York Heart Association class III heart failure. His current medications include captopril 20 mg, furosemide 40 mg, potassium chloride 10 mg twice daily, rosuvastatin 20 mg, and aspirin 81 mg. He reports that he generally feels well and has not had any recent worsening of his symptoms. His blood pressure is 132/85 mm Hg and heart rate is 84/min. Physical examination is unremarkable except for trace pitting edema of the bilateral lower extremities. What other medication should be added to his heart failure regimen?
- A. Losartan
- B. Metoprolol tartrate
- C. Isosorbide dinitrate/hydralazine
- D. Metoprolol succinate (Correct Answer)
- E. Digoxin
Quality measures in heart failure Explanation: ***Metoprolol succinate***
- Current guidelines recommend adding a **beta-blocker** (specifically metoprolol succinate, carvedilol, or bisoprolol) as part of guideline-directed medical therapy (GDMT) for **NYHA class II-IV heart failure with reduced ejection fraction (HFrEF)**.
- This patient is already on an **ACE inhibitor and diuretic** but is missing a **beta-blocker**, which is a cornerstone of HFrEF therapy.
- Beta-blockers **reduce mortality and morbidity** in HFrEF by counteracting chronic sympathetic activation, improving cardiac remodeling, and reducing heart rate.
- Metoprolol succinate is the **long-acting formulation** preferred for chronic heart failure management.
***Incorrect Option: Losartan***
- The patient is already on an **ACE inhibitor (captopril)**, which acts on the renin-angiotensin-aldosterone system.
- Adding an **ARB (angiotensin receptor blocker)** like losartan to an ACE inhibitor is generally not recommended due to increased risk of hyperkalemia, hypotension, and renal dysfunction without significant additional benefit.
- ARBs are typically used as an alternative when patients cannot tolerate ACE inhibitors (e.g., due to cough or angioedema).
***Incorrect Option: Metoprolol tartrate***
- While metoprolol tartrate is a beta-blocker, it is a **short-acting formulation** typically used for acute conditions like hypertension or angina.
- For **chronic heart failure management**, **long-acting beta-blockers** such as metoprolol succinate are preferred due to sustained therapeutic levels, better adherence, and proven mortality benefit in clinical trials.
***Incorrect Option: Isosorbide dinitrate/hydralazine***
- This combination is primarily indicated for **African American patients with NYHA class III-IV HFrEF** who remain symptomatic despite optimal therapy, or as an alternative in patients who cannot tolerate ACE inhibitors/ARBs.
- While the patient has class III heart failure, he is **not yet on a beta-blocker**, which is a more fundamental component of GDMT and should be added first.
- This combination is typically added as a fourth-line agent.
***Incorrect Option: Digoxin***
- Digoxin is considered for patients with **HFrEF who remain symptomatic** despite optimized therapy with ACE inhibitors/ARBs, beta-blockers, and mineralocorticoid receptor antagonists (MRAs).
- It primarily helps **improve symptoms and reduce hospitalizations** but does not reduce mortality.
- Since this patient is not yet on a beta-blocker, adding the beta-blocker takes priority.
Quality measures in heart failure US Medical PG Question 7: A 63-year-old woman presents with dyspnea on exertion. She reports that she used to work in her garden without any symptoms, but recently she started to note dyspnea and fatigue after working for 20–30 minutes. She has type 2 diabetes mellitus diagnosed 2 years ago but she does not take any medications preferring natural remedies. She also has arterial hypertension and takes torsemide 20 mg daily. The weight is 88 kg and the height is 164 cm. The vital signs include: blood pressure is 140/85 mm Hg, heart rate is 90/min, respiratory rate is 14/min, and the temperature is 36.6℃ (97.9℉). Physical examination is remarkable for increased adiposity, pitting pedal edema, and present S3. Echocardiography shows a left ventricular ejection fraction of 51%. The combination of which of the following medications would be a proper addition to the patient’s therapy?
- A. Metoprolol and indapamide
- B. Enalapril and bisoprolol (Correct Answer)
- C. Spironolactone and fosinopril
- D. Indapamide and amlodipine
- E. Valsartan and spironolactone
Quality measures in heart failure Explanation: ***Enalapril and bisoprolol***
- This patient presents with **heart failure with preserved ejection fraction (HFpEF)**, characterized by symptoms of heart failure (dyspnea, fatigue, edema, S3 sound) with an LVEF >50%. She also has **uncontrolled hypertension** (BP 140/85) and a **heart rate of 90/min**.
- **Important:** Unlike HFrEF, **ACE inhibitors and beta-blockers have NOT demonstrated mortality benefit in HFpEF** (CHARM-Preserved, PEP-CHF trials). However, they remain important for **blood pressure control** and **symptom management** in patients with HFpEF and comorbid hypertension.
- **Enalapril** (ACE inhibitor) helps control blood pressure through reduction of preload and afterload. **Bisoprolol** (beta-blocker) provides **heart rate control** (patient's HR is 90/min) and further blood pressure reduction. Both medications address her inadequately controlled hypertension while managing symptoms.
- **Note:** Current guidelines emphasize SGLT2 inhibitors as first-line therapy for HFpEF (not offered here), along with diuretics for volume management (patient is already on torsemide) and aggressive treatment of comorbidities like hypertension and diabetes.
*Metoprolol and indapamide*
- Metoprolol is a beta-blocker that could help with rate and blood pressure control. However, **indapamide is a thiazide-like diuretic** that is redundant since the patient is already on **torsemide** (a loop diuretic) for volume management.
- This combination lacks an **ACE inhibitor or ARB** for optimal blood pressure control and neurohormonal modulation, which is important even in HFpEF for managing hypertension and its consequences.
*Spironolactone and fosinopril*
- **Spironolactone** (mineralocorticoid receptor antagonist) showed modest benefit in reducing HF hospitalizations in the TOPCAT trial for HFpEF. **Fosinopril** is an ACE inhibitor appropriate for blood pressure control.
- However, the patient has a **heart rate of 90/min**, indicating need for **rate control** which neither spironolactone nor fosinopril provides. A **beta-blocker would be more appropriate** to address both rate control and blood pressure.
- Additionally, while spironolactone has some evidence in HFpEF, the combination with an ACE inhibitor **without rate control** is suboptimal for this patient's presentation.
*Indapamide and amlodipine*
- **Indapamide** (thiazide-like diuretic) is **redundant** since the patient is already on torsemide. **Amlodipine** (calcium channel blocker) is effective for hypertension but can cause **peripheral edema**, which this patient already has (pitting pedal edema).
- **Calcium channel blockers are not recommended in heart failure** due to lack of mortality benefit and potential to worsen fluid retention. This combination does not address the underlying HFpEF pathophysiology or provide optimal symptom management.
*Valsartan and spironolactone*
- **Valsartan** (ARB) is appropriate for blood pressure control and is an alternative to ACE inhibitors. **Spironolactone** has modest evidence for reducing hospitalizations in HFpEF (TOPCAT trial).
- However, similar to the fosinopril/spironolactone combination, this lacks a **beta-blocker for heart rate control** (patient's HR is 90/min). Rate control is important for optimizing diastolic filling time in HFpEF and controlling blood pressure.
- While this combination has theoretical benefits, **enalapril and bisoprolol** better addresses both blood pressure control and rate control simultaneously.
Quality measures in heart failure US Medical PG Question 8: A 35-year-old alcoholic patient presents with high-output cardiac failure, tachycardia, a bounding pulse, and warm extremities. Blood work reveals vitamin deficiency. Which of the following vitamin deficiencies is most likely associated with such a clinical presentation?
- A. Thiamine (Correct Answer)
- B. Riboflavin
- C. Vitamin B12
- D. Vitamin D
- E. Niacin
Quality measures in heart failure Explanation: ***Thiamine***
- **Thiamine deficiency**, particularly in alcoholics, can lead to **wet beriberi**, characterized by **high-output cardiac failure** due to peripheral vasodilation, resulting in symptoms like tachycardia, bounding pulse, and warm extremities.
- Thiamine (vitamin B1) is a crucial cofactor in carbohydrate metabolism, and its deficiency impairs myocardial energy production and causes systemic vasodilation.
*Riboflavin*
- **Riboflavin deficiency** (ariboflavinosis) typically presents with **cheilosis**, glossitis, angular stomatitis, and seborrheic dermatitis, and is not directly associated with high-output cardiac failure.
- While it can occur in alcoholics, cardiac failure is not a prominent feature.
*Vitamin B12*
- **Vitamin B12 deficiency** primarily causes **megaloblastic anemia** and neurological symptoms such as **peripheral neuropathy**, ataxia, and cognitive impairment, rather than high-output cardiac failure.
- Cardiac manifestations are usually due to severe anemia leading to compensatory high output, but not the primary cause as seen in thiamine deficiency.
*Vitamin D*
- **Vitamin D deficiency** is associated with **osteomalacia** in adults and rickets in children, leading to bone pain, muscle weakness, and increased fracture risk.
- It does not cause high-output cardiac failure or related cardiovascular symptoms.
*Niacin*
- **Niacin deficiency** (pellagra) is characterized by the "3 Ds": **dermatitis**, **diarrhea**, and **dementia**, along with glossitis and stomatitis.
- While cardiovascular symptoms can occur in severe cases, high-output cardiac failure with a bounding pulse is not a typical hallmark of pellagra.
Quality measures in heart failure US Medical PG Question 9: A 42-year-old biochemist receives negative feedback from a senior associate on a recent project. He is placed on probation within the company and told that he must improve his performance on the next project to remain with the company. He is distraught and leaves his office early. When he gives an account of the episode to his wife, she says, “I'll always be proud of you no matter what because I know that you always try your best.” Later that night, he tearfully accuses her of believing that he is a failure. Which of the following psychological defense mechanisms is he demonstrating?
- A. Transference
- B. Displacement
- C. Denial
- D. Passive aggression
- E. Projection (Correct Answer)
Quality measures in heart failure Explanation: ***Projection***
- The man is attributing his own **unacceptable feelings** (believing he is a failure) onto his wife, despite her supportive statement.
- He is seeing his own internal inadequacy reflected in her words, rather than accepting her comfort.
- This is projection because he interprets her supportive words as criticism, projecting his self-judgment onto her.
*Transference*
- This involves redirecting feelings and desires from one person (often a past significant figure) to a new situation or person, which is not depicted here.
- The man's reaction is specific to the current stressful situation and his own feelings, not an unconscious redirection of past relationship patterns.
*Displacement*
- This defense mechanism involves redirecting negative emotions from the original source (his boss/work) to a less threatening target (his wife).
- While this scenario might superficially resemble displacement, the key issue is that he is **misinterpreting** her supportive words as criticism, not simply redirecting anger.
- The distortion of her message indicates projection rather than pure displacement of emotion.
*Denial*
- Denial occurs when an individual refuses to acknowledge a painful reality or feeling.
- The man is clearly acknowledging his distress ("tearfully accuses") and his fear of failure, rather than refusing to accept it.
*Passive aggression*
- This involves expressing negative feelings indirectly, often through stubbornness, procrastination, or masked resistance.
- The man's accusation is direct and emotionally charged, not an indirect expression of hostility.
Quality measures in heart failure US Medical PG Question 10: A 21-year-old woman presents with palpitations and anxiety. She had a recent outpatient ECG that was suggestive of supraventricular tachycardia, but her previous physician failed to find any underlying disease. No other significant past medical history. Her vital signs include blood pressure 102/65 mm Hg, pulse 120/min, respiratory rate 17/min, and temperature 36.5℃ (97.7℉). Electrophysiological studies reveal an atrioventricular nodal reentrant tachycardia. The patient refuses an ablation procedure so it is decided to perform synchronized cardioversion with consequent ongoing management with verapamil. Which of the following ECG features should be monitored in this patient during treatment?
- A. Amplitude and direction of the T wave
- B. Length of QRS complex
- C. Length of QT interval
- D. Length of PR interval (Correct Answer)
- E. QRS complex amplitude
Quality measures in heart failure Explanation: ***Length of PR interval***
- Verapamil is a **non-dihydropyridine calcium channel blocker** that primarily acts on the **AV node** to slow conduction.
- Monitoring the **PR interval** is crucial because excessive slowing of AV nodal conduction can lead to **AV block**, which is indicated by a prolonged PR interval.
*Amplitude and direction of the T wave*
- Changes in T-wave amplitude and direction are often associated with **myocardial ischemia** or **electrolyte imbalances**, which are not the primary concerns with verapamil.
- While verapamil can affect repolarization, the most direct and common adverse effect related to its mechanism of action on the AV node is not primarily reflected in T-wave changes.
*Length of QRS complex*
- The QRS complex duration primarily reflects **ventricular depolarization** and is typically affected by medications that alter conduction through the His-Purkinje system or within the ventricles, such as antiarrhythmics like **flecainide** or **amiodarone**.
- Verapamil's main action is on the AV node, so it generally does not significantly prolong the QRS complex unless there is pre-existing conduction system disease.
*Length of QT interval*
- The QT interval represents **ventricular repolarization**, and its prolongation can lead to **Torsades de Pointes**, a life-threatening arrhythmia.
- While many antiarrhythmics can prolong the QT interval, **verapamil is not known to significantly prolong the QT interval** and is generally considered safe in this regard.
*QRS complex amplitude*
- Changes in QRS amplitude can indicate conditions like **pericardial effusion**, **cardiomyopathy**, or changes in ventricular mass.
- These are generally not direct or common side effects of verapamil therapy, which primarily focuses on AV nodal conduction.
More Quality measures in heart failure US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
